Biohaven’s ion channel drug fails pivotal bipolar mania study
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report. The Phase 2/3 study included an estimated 256 people who were voluntarily hospitalized ...
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report.
The Phase 2/3 study included an estimated 256 people who were voluntarily hospitalized ...
